Aurora Spine Corp. (ASG) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.98 k

Shareholding (Jun 2025)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 9.74% of over the last 5 years

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 24 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.34

Return on Equity

-24.01%

Price to Book

4.37

Revenue and Profits:

Net Sales:

6 Million

(Quarterly Results - Jun 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1.92%

6 Months

-17.19%

1 Year

-35.37%

2 Years

-32.05%

3 Years

-39.77%

4 Years

-14.52%

5 Years

-3.64%

Aurora Spine Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

16.30%

EBIT Growth (5y)

9.74%

EBIT to Interest (avg)

-1.83

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.35

Sales to Capital Employed (avg)

2.50

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.16

EV to EBIT

-23.02

EV to EBITDA

24.20

EV to Capital Employed

3.36

EV to Sales

0.94

PEG Ratio

Dividend Yield

ROCE (Latest)

-14.61%

ROE (Latest)

-24.01%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -1.59% vs -4.55% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 40.00% vs 44.44% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.20",
          "val2": "6.30",
          "chgp": "-1.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.20",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.30",
          "val2": "-0.50",
          "chgp": "40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-29.00%",
          "val2": "-61.70%",
          "chgp": "3.27%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 22.96% vs 1.03% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 39.13% vs -15.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.10",
          "val2": "19.60",
          "chgp": "22.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.50",
          "val2": "-0.60",
          "chgp": "183.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.40",
          "val2": "-2.30",
          "chgp": "39.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-38.40%",
          "val2": "-103.00%",
          "chgp": "6.46%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

6.20

6.30

-1.59%

Operating Profit (PBDIT) excl Other Income

0.20

-0.00

Interest

0.10

Exceptional Items

-0.00

Consolidate Net Profit

-0.30

-0.50

40.00%

Operating Profit Margin (Excl OI)

-29.00%

-61.70%

3.27%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -1.59% vs -4.55% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 40.00% vs 44.44% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

24.10

19.60

22.96%

Operating Profit (PBDIT) excl Other Income

0.50

-0.60

183.33%

Interest

0.20

Exceptional Items

-0.20

0.00

Consolidate Net Profit

-1.40

-2.30

39.13%

Operating Profit Margin (Excl OI)

-38.40%

-103.00%

6.46%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 22.96% vs 1.03% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 39.13% vs -15.00% in Dec 2023

All Annual Results

Company CV

About Aurora Spine Corp.

Aurora Spine Corp.

Pharmaceuticals & Biotechnology

Aurora Spine Corporation is a Canada-based holding company. The Company's segment includes its focus on the development and sale of minimally invasive, interspinous fusion systems and devices. The Company's interspinous process (ISP) lumbar fusion devices include the ZIP and ZIP ULTRA, the ZIP LP and the ZIP-51. In addition, the Company offers a line of interbody products, such as the TiNano product line, including EOS, Echo and EchoXL for the lumbar section of the spine, and discovery for cervical procedures. Its product lines include ISP lumbar fusion devices; polyether ether ketone (PEEK) interbody cages, and Stand-alone (SA) Cervical and Lumbar devices. Its interbody cage products are used to fill the space between vertebrae after degenerative disc material has been removed. Its VOX is a minimally invasive lateral lumbar interbody fusion (LLIF) system featuring TiNano titanium spray coating technology. It characterizes business in the United States and outside the United States.

Company Coordinates

Company Details

20 HOLLY STREET, SUITE 300 , TORONTO ON : M4S 3B1

Tel: 1 760 4242004

https://auroraspine.us/

Registrar Details